Summary of Key Information:
Reporting Period (Quarter/Year): Quarter Ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion:
Clean Review Opinion - Deloitte Haskins & Sells LLP issued an unmodified review report stating nothing came to their attention that causes them to believe the financial results contain any material misstatement.
Key Financial Highlights [INR Million]:
Standalone Results:
Revenue from Operations: ₹28,722 million (11% increase from ₹25,883 million in Q1 FY26)
- Sale of products: ₹27,235 million
- Other operating revenues: ₹1,487 million
Total Income: ₹29,959 million
Net Profit: ₹3,396 million (11.7% decrease from ₹3,847 million in Q1 FY26)
EPS: ₹3.38 (Basic and Diluted)
Other Equity: Not specified for current quarter
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Consolidated Results:
Revenue from Operations: ₹80,170 million (21.9% increase from ₹65,737 million in Q1 FY26)
- Sale of products: ₹78,020 million
- Other operating revenues: ₹2,150 million
Total Income: ₹81,231 million
Net Profit: ₹9,398 million (35.9% decrease from ₹14,668 million in Q1 FY26)
EPS: ₹9.35 (Basic and Diluted)
Other Equity: ₹270,108 million (as of March 31, 2026)
Cash and Cash Equivalents: Not disclosed
Debt: Not disclosed
Segment-wise Performance [INR Million]:
Segment Revenue:
- Pharmaceuticals: ₹62,981 million
- Consumer products: ₹14,359 million
- Medical technologies: ₹2,830 million
- Total: ₹80,170 million
Segment Results:
- Pharmaceuticals: ₹12,452 million profit
- Consumer products: ₹1,613 million profit
- Medical technologies: ₹(817) million loss
- Total profit before tax before exceptional items: ₹13,248 million
Segment Assets:
- Pharmaceuticals: ₹390,479 million
- Consumer products: ₹104,575 million
- Medical technologies: ₹62,409 million
- Total: ₹557,463 million
Segment Liabilities:
- Pharmaceuticals: ₹154,114 million
- Consumer products: ₹45,200 million
- Medical technologies: ₹63,860 million
- Total: ₹263,174 million
Corporate Actions:
Equity Share Buyback: The Company completed buyback of 8,730,158 equity shares (0.87% of total equity shares) at ₹1,260 per share, aggregating to ₹11,063 million including expenses. Shares were extinguished on June 18, 2026.
Dividend: Not declared
Other Significant Information:
Exceptional Items (Standalone):
None for current quarter (Q1 FY27)
Exceptional Items (Consolidated) [INR Million]:
- Total: ₹182 million
- Includes provision for antitrust lawsuit settlement by Zydus Pharmaceuticals Inc.: ₹559 million
- Less receipt from Teva settlement: ₹(1,468) million
Tax Considerations:
The Company computed provision for income tax under section 115BAA of Income Tax Act, 1961, making current quarter tax expenses not comparable with previous periods.
Recent Acquisitions:
1. Assertio Holdings, Inc. acquisition completed on June 16, 2026 for approximately USD 166.4 million
2. Agenus biologics manufacturing facilities acquisition completed on January 15, 2026 for USD 75 million upfront
3. Comfort Click Limited acquisition completed on August 29, 2025 for GBP 239 million
4. Amplitude Surgical SA became wholly owned subsidiary on October 24, 2025 for EUR 300 million
Legal Settlements:
1. Zydus Pharmaceuticals USA, Inc. settled with Astellas Pharma Inc. for Myrbetriq® for USD 120 million
2. Zydus Worldwide DMCC received USD 15.5 million settlement from Teva Pharmaceutical Industries Ltd.
3. Zydus Pharmaceuticals Inc. reached in-principle agreement to resolve four class action antitrust lawsuits
Labour Code Impact:
New Labour Codes implementation resulted in one-time increase in gratuity and leave encashment liability of ₹849 million at consolidated level.
Entities in Consolidation:
The consolidated results include 1 parent company, 86 subsidiaries, and 4 joint ventures as listed in the annexure to the auditor's report.